Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma
Authors:
- 20 February 2019
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 33 (5) , 1273-1277
Abstract
Multiple myeloma (MM) is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma (SMM), or solitary plasmacytoma (SPC). There is a lack of data regarding impact of these pre-existing monoclonal gammopathies (MGs) on MM outcomes. Patients with prior diagnosis of MGUS, SMM, or PC from 1973 to 2015 (cases) were identified from our institution’s database and compared to those without a known MG (controls). The primary outcome of interest was overall survival (OS). Multivariate analysis was performed to ascertain factors impacting all-cause mortality. We identified 774 patients with a prior diagnosis of MGUS, SMM or SPC (cases) and a control population (1:2) matched for the year of diagnosis (n = 1548). After a median follow-up of 81 months, the cases showed a longer median OS than the controls (71 months vs. 56 months). The improved OS was limited to those with a known prior diagnosis of SMM (80 months) and SPC (95 months), compared to MGUS (60 months). Multivariable analysis revealed that MM patients with known prior MG had less overall mortality than those without, and this was limited to prior SMM/SPC group (HR 0.68, 95% CI: 0.50–0.93), as compared to the MGUS group (HR 0.83, 95% CI: 0.66–1.05).Keywords
This publication has 18 references indexed in Scilit:
- Long-Term Follow-up of Monoclonal Gammopathy of Undetermined SignificanceNew England Journal of Medicine, 2018
- The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple MyelomaJAMA Oncology, 2015
- Determining the Clinical Significance of Monoclonal Gammopathy of Undetermined Significance: A SEER–Medicare Population AnalysisClinical Lymphoma Myeloma and Leukemia, 2015
- International Myeloma Working Group updated criteria for the diagnosis of multiple myelomaThe Lancet Oncology, 2014
- Improved long-term survival in multiple myeloma up to the age of 80 yearsLeukemia, 2014
- Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patientsLeukemia, 2013
- Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective studyBlood, 2009
- Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple MyelomaNew England Journal of Medicine, 2007
- Prevalence of Monoclonal Gammopathy of Undetermined SignificanceNew England Journal of Medicine, 2006
- A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined SignificanceNew England Journal of Medicine, 2002